MiMedx Group, Inc.
MDXGNASDAQHealthcare● Active
$3.79
+$0.05(+1.31%)
Market Cap$564355375
P/E Ratio—
52W High$7.99
52W Low$3.03
MiMedx Group, Inc. (MDXG) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MDXG · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
-$0.05
Est. -$0.07 · +28.6%
Revenue
$0.06B
Est. $0.07B · -10.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 9-Quarter EPS Beat Streak
MDXG reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | -$0.03 | — | — | — | $0.06B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | -$0.07 | -$0.05 | +28.6% | $0.06B | $0.07B | -10.3% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $0.09 | $0.14 | +55.6% | $0.12B | $0.11B | +10.6% |
| ▲ Q4 FY2025 | Oct 29, 2025 | $0.07 | $0.15 | +114.3% | $0.11B | $0.11B | +6.3% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.06 | $0.10 | +66.7% | $0.10B | $0.09B | +5.7% |
| — Q2 FY2025 | Apr 30, 2025 | $0.06 | $0.06 | +0.0% | $0.09B | $0.09B | +2.2% |
| — Q1 FY2025 | Feb 26, 2025 | $0.07 | $0.07 | +0.0% | $0.09B | $0.09B | +3.9% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $0.04 | $0.05 | +13.6% | $0.08B | $0.09B | -6.0% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.07
EPS Surpr.
+28.6%
Revenue
$0.06B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$0.14
EPS Est.
$0.09
EPS Surpr.
+55.6%
Revenue
$0.12B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
$0.15
EPS Est.
$0.07
EPS Surpr.
+114.3%
Revenue
$0.11B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.10
EPS Est.
$0.06
EPS Surpr.
+66.7%
Revenue
$0.10B
Q2 FY2025
Apr 30, 2025
EPS Actual
$0.06
EPS Est.
$0.06
EPS Surpr.
+0.0%
Revenue
$0.09B
Q1 FY2025
Feb 26, 2025
EPS Actual
$0.07
EPS Est.
$0.07
EPS Surpr.
+0.0%
Revenue
$0.09B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$0.05
EPS Est.
$0.04
EPS Surpr.
+13.6%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.09 | $0.09 | $0.09 | 3 |
| Q3 FY2028 | $0.06 | $0.06 | $0.06 | 2 |
| Q2 FY2028 | $0.03 | $0.03 | $0.03 | 2 |
| Q1 FY2028 | $0.02 | $0.02 | $0.02 | 3 |
| Q4 FY2027 | $0.05 | $0.06 | $0.06 | 2 |
| Q3 FY2027 | $0.03 | $0.03 | $0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +28.6% | $3.40 | $3.09 | -9.12% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +55.6% | $5.35 | $5.28 | -1.31% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +114.3% | $6.88 | $7.19 | +4.51% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +66.7% | $6.67 | $6.52 | -2.25% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +0.0% | $6.92 | $6.88 | -0.58% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +0.0% | $7.96 | $8.01 | +0.63% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +13.6% | $5.81 | $5.69 | -2.07% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +0.0% | $7.59 | $7.45 | -1.84% |
Q2 FY2026-9.12%
Report Date
Apr 29, 2026
EPS Beat/Miss
+28.6%
Price Before
$3.40
Price After
$3.09
Q1 FY2026-1.31%
Report Date
Feb 25, 2026
EPS Beat/Miss
+55.6%
Price Before
$5.35
Price After
$5.28
Q4 FY2025+4.51%
Report Date
Oct 29, 2025
EPS Beat/Miss
+114.3%
Price Before
$6.88
Price After
$7.19
Q3 FY2025-2.25%
Report Date
Jul 30, 2025
EPS Beat/Miss
+66.7%
Price Before
$6.67
Price After
$6.52
Q2 FY2025-0.58%
Report Date
Apr 30, 2025
EPS Beat/Miss
+0.0%
Price Before
$6.92
Price After
$6.88
Q1 FY2025+0.63%
Report Date
Feb 26, 2025
EPS Beat/Miss
+0.0%
Price Before
$7.96
Price After
$8.01
Q4 FY2024-2.07%
Report Date
Oct 30, 2024
EPS Beat/Miss
+13.6%
Price Before
$5.81
Price After
$5.69
Q3 FY2024-1.84%
Report Date
Jul 31, 2024
EPS Beat/Miss
+0.0%
Price Before
$7.59
Price After
$7.45
Avg Beat Reaction-1.50%
Beat Rate8 / 8 quarters
Largest Move-9.12% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MDXG ends December
MiMedx Group, Inc. (MDXG) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $-0.05 — beating the analyst consensus of $-0.07 by +28.6%. MDXG has beaten EPS estimates for 9 consecutive quarters. The next MDXG earnings date is expected around September 1, 2026.
Each quarter, investors track MDXG earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MDXG revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MDXG's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MDXG earnings · 5 questionsMiMedx Group, Inc.'s next earnings report is expected around September 1, 2026. MDXG typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MDXG historically reports after market close (AMC).
MDXG earnings datewhen is MDXG earningsMDXG next earnings datewhen does MDXG report earningsMDXG earnings calendar
▸ Source: FMP · MiMedx Group, Inc. SEC filings · US GAAP · MiMedx Group, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026